Healthcare [ 4/11 ] | Biotechnology [ 53/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | 0.02 Increased by +102.15% | -0.24 Increased by +451.39% |
| Mar 13, 23 | -0.65 Increased by +84.34% | -0.82 Increased by +25.28% |
| Nov 10, 22 | -0.92 Increased by +40.90% | -0.97 Increased by +5.31% |
| Aug 11, 22 | -0.93 | -0.87 Decreased by -7.93% |
| May 12, 22 | -0.93 | -0.69 Decreased by -50.41% |
| Mar 30, 22 | -4.15 | -0.64 Decreased by -856.93% |
| Jan 10, 22 | -1.56 | -0.64 Decreased by -223.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 71.43 M Increased by +N/A% | 1.57 M Increased by +103.29% | Increased by +2.20% Decreased by N/A% |
| Dec 31, 22 | 21.89 M Increased by +N/A% | -42.70 M Increased by +51.42% | Decreased by -195.13% Decreased by N/A% |
| Sep 30, 22 | 345.00 K Increased by +N/A% | -53.76 M Decreased by -130.09% | Decreased by -15.58 K% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -54.07 M Decreased by -114.08% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -47.85 M Decreased by -195.80% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -87.90 M Decreased by -923.06% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 - | -23.36 M - | Decreased by N/A% - |
| Jun 30, 21 | 0.00 - | -25.26 M - | Decreased by N/A% - |
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.